What the business is, and whether it's a good one at a fair price.
Develops, manufactures and sells branded and generic pharmaceutical formulations across India, North America, Europe and emerging markets. FY26 consolidated revenue of Rs 16,982.51 crore grew 27.5% YoY, driven heavily by North America jumping 136.6% YoY on recognition of an AbbVie licensing deal for ISB 2001 worth USD 700 million upfront and potential USD 1.925 billion total. India revenue fell 17% YoY to Rs 37,237 million, while Europe and Emerging Markets posted 21.4% and 13.7% growth respectively. The portfolio spans branded speciality products such as RYALTRIS nasal spray and WINLEVI, plus a US generics pipeline that launched 13 products in FY26 and 9 in Q1 FY27, including the first generic FloVent HFA with 180-day exclusivity. Manufacturing includes a Goa facility inspected by the US FDA in June 2026 with six procedural observations and a Monroe facility classified VAI after inspection. R&D spend in Q1 FY27 was Rs 2,494 million. Cost structure is led by other operating expenses at 24.1% of revenue, employee costs at 21.1% and materials at 17.4%, with capex at 8.0% of revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from GLENMARK PHARMACEUTICALS's filed financials and exchange disclosures
GLENMARK PHARMACEUTICALS is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol GLENMARK.
Yes. Over the trailing twelve months GLENMARK PHARMACEUTICALS reported a net profit of ₹1,798 Cr on revenue of ₹17,737 Cr.
Yes. The dividend yield is 0.21% at the current price. It paid out 10% of its profit as dividend in FY26.
Effectively yes. It holds ₹1,175 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, GLENMARK PHARMACEUTICALS ranks 108 of 169 in Pharmaceuticals — cheaper than 36% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session GLENMARK PHARMACEUTICALS moves 0.87% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by GLENMARK PHARMACEUTICALS appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
